Research Articles
In-depth guides on GIP/GLP-1 dual agonist research, tirzepatide clinical trial data, mechanism of action, and metabolic health science.
All Research Articles
Tirzepatide Research Peptide Reconstitution Guide
Research protocol for reconstituting tirzepatide lyophilized peptides (15mg, 30mg, 60mg) with bacteriostatic water for laboratory applications.
GIP Receptor Biology: Why the Second Agonist Target Matters
Understanding the GIP receptor's role in adipose tissue, pancreatic function, and why GIP co-agonism enhances tirzepatide's metabolic effects.
SURPASS-CVOT: Tirzepatide Cardiovascular Outcomes Research
Analysis of the SURPASS-CVOT trial comparing tirzepatide vs. dulaglutide for cardiovascular outcomes in type 2 diabetes with established CVD.
Tirzepatide vs Semaglutide: Head-to-Head Clinical Trial Data
Direct comparison of tirzepatide and semaglutide efficacy data from SURMOUNT-5, SURMOUNT-1, and STEP-1 trials, with mechanistic analysis of why dual GLP-1/GIP agonism outperforms GLP-1-only therapy.
GLP-1 Receptor Mechanism: How Incretin Agonists Drive Weight Loss
A detailed mechanistic review of GLP-1 receptor expression across brain, pancreas, and gut tissues, cAMP signaling pathways, satiety circuitry, and how GLP-1-only vs dual agonist compounds differ in their downstream effects.
Tirzepatide Research Dosing Escalation Protocol
Detailed tirzepatide dose escalation schedule from 2.5 mg through 15 mg, side effect profiles by dose tier, and concentration calculations for 15 mg, 30 mg, and 60 mg research vials.
Incretin Hormones: The Science Behind GIP and GLP-1
A comprehensive review of incretin hormone biology including the discovery history of GIP and GLP-1, secretion patterns from K-cells and L-cells, the incretin effect in health vs. type 2 diabetes, and how pharmacological agonists overcome native peptide instability.
Tirzepatide and Type 2 Diabetes: HbA1c Reduction Research Data
Comprehensive analysis of SURPASS-1 through SURPASS-5 glycemic endpoint data, cross-agent HbA1c reduction comparisons, and preclinical beta cell preservation findings for tirzepatide.
Managing GLP-1 Agonist Nausea: Research Protocol Strategies
Mechanistic review of GLP-1-induced nausea via the area postrema, evidence for tirzepatide's lower nausea burden through GIP co-agonism, optimal dose escalation timing strategies, and cross-trial nausea rate data.
Tirzepatide Effects on Adipose Tissue: Fat Loss Mechanisms
Detailed review of tirzepatide's differential effects on visceral and subcutaneous adipose tissue, SURMOUNT-NASH liver fat data, GIP receptor biology in adipocytes, and body composition changes including lean mass preservation.
Research Peptide Storage and Stability: Tirzepatide & GLP-1 Agonists
Comprehensive guidelines for lyophilized and reconstituted tirzepatide and GLP-1 agonist storage, stability data by temperature and humidity, freeze-thaw cycle impacts, and a comparison of bacteriostatic vs sterile water as diluents.
Explore the Research Compounds
Research-grade tirzepatide and bacteriostatic water — the complete research protocol. Third-party tested, ≥98% purity.